PL2564855T3 - Leczenie niewydolności serca u ssaków niebędących ludźmi z użyciem antagonisty aldosteronu - Google Patents

Leczenie niewydolności serca u ssaków niebędących ludźmi z użyciem antagonisty aldosteronu

Info

Publication number
PL2564855T3
PL2564855T3 PL12180375T PL12180375T PL2564855T3 PL 2564855 T3 PL2564855 T3 PL 2564855T3 PL 12180375 T PL12180375 T PL 12180375T PL 12180375 T PL12180375 T PL 12180375T PL 2564855 T3 PL2564855 T3 PL 2564855T3
Authority
PL
Poland
Prior art keywords
treatment
heart failure
human mammals
aldosterone antagonist
aldosterone
Prior art date
Application number
PL12180375T
Other languages
English (en)
Inventor
Patricia Ovaert
Florence Bernay
Jérôme Guyonnet
Original Assignee
Ceva Sante Animale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ceva Sante Animale filed Critical Ceva Sante Animale
Publication of PL2564855T3 publication Critical patent/PL2564855T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
PL12180375T 2007-06-26 2008-06-25 Leczenie niewydolności serca u ssaków niebędących ludźmi z użyciem antagonisty aldosteronu PL2564855T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0704584A FR2917975B1 (fr) 2007-06-26 2007-06-26 Compositions et traitement de l'insuffisance cardiaque chez les animaux mammiferes non humains
US4841908P 2008-04-28 2008-04-28
EP12180375.3A EP2564855B1 (fr) 2007-06-26 2008-06-25 Traitement de l'insuffisance cardiaque chez les animaux mammiferes non humains par un antagoniste de l'aldostérone
EP08774270.6A EP2170349B1 (fr) 2007-06-26 2008-06-25 Traitement de l'insuffisance cardiaque chez les animaux mammiferes non humains par un antagoniste de l'aldostérone

Publications (1)

Publication Number Publication Date
PL2564855T3 true PL2564855T3 (pl) 2016-07-29

Family

ID=38951459

Family Applications (4)

Application Number Title Priority Date Filing Date
PL12180334T PL2564854T3 (pl) 2007-06-26 2008-06-25 Leczenie niewydolności serca u ssaków niebędących ludźmi z użyciem antagonisty aldosteronu
PL12180487T PL2564856T3 (pl) 2007-06-26 2008-06-25 Leczenie niewydolności serca u ssaków niebędących ludźmi z użyciem antagonisty aldosteronu
PL08774270T PL2170349T3 (pl) 2007-06-26 2008-06-25 Leczenie wad serca u ssaków innych niż człowiek antagonistą aldosteronu
PL12180375T PL2564855T3 (pl) 2007-06-26 2008-06-25 Leczenie niewydolności serca u ssaków niebędących ludźmi z użyciem antagonisty aldosteronu

Family Applications Before (3)

Application Number Title Priority Date Filing Date
PL12180334T PL2564854T3 (pl) 2007-06-26 2008-06-25 Leczenie niewydolności serca u ssaków niebędących ludźmi z użyciem antagonisty aldosteronu
PL12180487T PL2564856T3 (pl) 2007-06-26 2008-06-25 Leczenie niewydolności serca u ssaków niebędących ludźmi z użyciem antagonisty aldosteronu
PL08774270T PL2170349T3 (pl) 2007-06-26 2008-06-25 Leczenie wad serca u ssaków innych niż człowiek antagonistą aldosteronu

Country Status (10)

Country Link
US (2) US20100183718A1 (pl)
EP (5) EP2564855B1 (pl)
JP (1) JP5876219B2 (pl)
AU (1) AU2008267227B2 (pl)
BR (1) BRPI0813882A2 (pl)
CA (1) CA2696961C (pl)
ES (4) ES2566923T3 (pl)
FR (1) FR2917975B1 (pl)
PL (4) PL2564854T3 (pl)
WO (1) WO2009000843A2 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1920785A1 (en) * 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
FR2917975B1 (fr) 2007-06-26 2009-10-16 Ceva Sante Animale Sa Compositions et traitement de l'insuffisance cardiaque chez les animaux mammiferes non humains
US20090270356A1 (en) * 2008-04-28 2009-10-29 Ceva Sante Animale Sa Compositions and treatments of heart failure in non-human mammal animals
SI2793866T1 (sl) * 2011-12-21 2016-01-29 Novartis Tiergesundheit Ag Nova kombinacija
WO2013135852A1 (en) * 2012-03-15 2013-09-19 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
FR2991179B1 (fr) * 2012-06-01 2016-11-11 Ceva Sante Animale Compositions veterinaires orales appetentes
WO2015007760A1 (en) 2013-07-19 2015-01-22 Boehringer Ingelheim Vetmedica Gmbh Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
PL3106150T3 (pl) 2013-12-04 2022-01-03 Boehringer Ingelheim Vetmedica Gmbh Ulepszone kompozycje farmaceutyczne pimobendanu
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
BR112020003235A2 (pt) 2017-08-17 2020-08-18 Ceva Sante Animale composições orais e métodos de preparação das mesmas
WO2024039311A1 (en) * 2022-08-16 2024-02-22 Imuneks Farma Ilac San. Ve Tic. A.S. Treatment of diseases caused by rna viruses

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652761C2 (de) 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
ES8101067A1 (es) 1978-08-25 1980-12-01 Thomae Gmbh Dr K Procedimiento para la preparacion de nuevos bencimidazoles sustituidos en posicion 5 o 6 con un anillo de piridazinona
FR2444047A1 (fr) * 1978-12-13 1980-07-11 Roussel Uclaf Nouveaux derives 2,2-dimethyl 19-nor steroides, leur procede de preparation et leur application comme medicaments
FI77669C (fi) 1983-04-13 1989-04-10 Ciba Geigy Ag 20-spiroxaner och analoger, som innehaoller en oeppen ring e, foerfarande foer deras framstaellning samt dessa innehaollande farmaceutiska preparat.
FR2569408B1 (fr) * 1984-08-24 1986-10-03 Roussel Uclaf Nouveaux steroides substitues en position 10 par un radical comportant une double ou triple liaison, leur procede de preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant
FR2594829B1 (fr) * 1986-02-24 1988-06-03 Roussel Uclaf Nouveaux steroides 9 (11) satures substitues en position 10 par un radical comportant une triple liaison, leur procede de preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant
GB8903130D0 (en) 1989-02-11 1989-03-30 Orion Yhtymae Oy Substituted pyridazinones
EP0808172B1 (en) 1995-02-10 2003-06-25 G.D. SEARLE & COMPANY Combination of angiotensin converting enzyme inhibitor and aldosterone antagonist for the treatment of ventricular hypertrophy
AU2001261434A1 (en) * 2000-05-11 2001-11-26 Pharmacia Corporation Aldosterone antagonist composition for release during aldosterone acrophase
ES2286270T3 (es) * 2001-07-19 2007-12-01 Pharmacia Corporation Combinacion de un antagonista del receptor de aldosterona y un inhibidor de la hmg coa reductasa.
WO2003070278A1 (en) * 2002-02-19 2003-08-28 Boehringer Ingelheim International Gmbh Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors
JP2004016070A (ja) * 2002-06-14 2004-01-22 Hitachi Ltd オーソログ遺伝子発現分布測定用オリゴヌクレオチドアレイ
WO2004017906A2 (en) * 2002-08-23 2004-03-04 Pharmacia Corporation Modulation of matrix metalloproteinase (mmp) activity with aldosterone blocker(s)
CL2004000366A1 (es) * 2003-02-26 2005-01-07 Pharmacia Corp Sa Organizada B USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
US20040214804A1 (en) * 2003-04-25 2004-10-28 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an anti-obesity agent
JP4783887B2 (ja) * 2005-02-17 2011-09-28 国立大学法人大阪大学 心筋組織の障害を抑制するための医薬組成物
FR2917975B1 (fr) 2007-06-26 2009-10-16 Ceva Sante Animale Sa Compositions et traitement de l'insuffisance cardiaque chez les animaux mammiferes non humains
US20090270356A1 (en) * 2008-04-28 2009-10-29 Ceva Sante Animale Sa Compositions and treatments of heart failure in non-human mammal animals

Also Published As

Publication number Publication date
EP2564856B1 (fr) 2016-01-20
EP2564855A1 (fr) 2013-03-06
AU2008267227B2 (en) 2014-05-01
EP2567701A2 (fr) 2013-03-13
AU2008267227A1 (en) 2008-12-31
ES2566924T3 (es) 2016-04-18
EP2170349B1 (fr) 2013-08-07
EP2564854B1 (fr) 2016-01-20
FR2917975A1 (fr) 2009-01-02
JP5876219B2 (ja) 2016-03-02
US20100183718A1 (en) 2010-07-22
FR2917975B1 (fr) 2009-10-16
CA2696961A1 (fr) 2008-12-31
PL2564854T3 (pl) 2016-07-29
WO2009000843A2 (fr) 2008-12-31
US20200016155A1 (en) 2020-01-16
EP2170349A2 (fr) 2010-04-07
ES2566960T3 (es) 2016-04-18
AU2008267227A8 (en) 2010-02-18
EP2564856A1 (fr) 2013-03-06
CA2696961C (fr) 2018-07-31
WO2009000843A3 (fr) 2009-07-23
ES2566923T3 (es) 2016-04-18
JP2010531333A (ja) 2010-09-24
PL2170349T3 (pl) 2014-01-31
PL2564856T3 (pl) 2016-07-29
EP2564855B1 (fr) 2016-01-20
EP2564854A1 (fr) 2013-03-06
EP2567701A3 (fr) 2013-07-03
BRPI0813882A2 (pt) 2015-01-13
ES2433383T3 (es) 2013-12-10

Similar Documents

Publication Publication Date Title
PL2564856T3 (pl) Leczenie niewydolności serca u ssaków niebędących ludźmi z użyciem antagonisty aldosteronu
HK1245147A1 (zh) 激活素-actrii的拮抗劑及在提高紅細胞水平中的用途
IL240870A0 (en) Human cardiovascular progenitor cells
IL243240A (en) Therapeutic peptidomimetic macrocycles
IL212748A0 (en) Peptidomimetic macrocycles with improved properties
IL211836A0 (en) Peptidomimetic macrocycles
GB0807854D0 (en) Detection of faults in an injector arrangement
IL212488A0 (en) Human progenitor t-cells
EP2407508A4 (en) RESIN COMPOSITION AND MULTILAYER STRUCTURE USING THE SAME
PT2708603T (pt) Utilizações em diagnóstico e terapia da gelsolina na insuficiência renal
EP2321125A4 (en) Fluoropolymer LAMINATE
EP2275481A4 (en) RESIN COMPOSITION AND MULTILAYER STRUCTURE OBTAINED USING THE COMPOSITION
ZA201109332B (en) Treatment of heart failure with normal ejection fraction
EP2343759A4 (en) BATTERY COMPONENT AND BATTERY
HK1154363A1 (en) Flame-retarding arrangement in reinforced-plastic boats
EP2415837A4 (en) RESIN COMPOSITION AND MULTILAYER STRUCTURE
EP2297306A4 (en) HUMAN FACILITATING CELLS
GB2451796B (en) Laminated structure with an interlayer
EP2453844A4 (en) MEDIA INCLUDING OLIGOELEMENTS FOR PROMOTING TISSUE REGENERATION IN MAMMALS
GB0916835D0 (en) An electrical assembly and improvements in or relating thereto
GB0814238D0 (en) Enhancement of electrochemical response
GB0812080D0 (en) Human propeeled boat
GB2461390B (en) Composite electrochemical cell
HK1157387A1 (en) Use of hsa-producing cells
GB0814895D0 (en) An improved hydrotherapy unit